NZ731060A - Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists - Google Patents

Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists

Info

Publication number
NZ731060A
NZ731060A NZ731060A NZ73106015A NZ731060A NZ 731060 A NZ731060 A NZ 731060A NZ 731060 A NZ731060 A NZ 731060A NZ 73106015 A NZ73106015 A NZ 73106015A NZ 731060 A NZ731060 A NZ 731060A
Authority
NZ
New Zealand
Prior art keywords
liver disease
fatty liver
glucocorticoid
receptor antagonists
disease treatment
Prior art date
Application number
NZ731060A
Other languages
English (en)
Inventor
Joseph K Belanoff
Hazel Hunt
Onno C Meijer
Den Heuvel Jose Van
Original Assignee
Corcept Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corcept Therapeutics Inc filed Critical Corcept Therapeutics Inc
Publication of NZ731060A publication Critical patent/NZ731060A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ731060A 2014-10-15 2015-10-14 Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists NZ731060A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462064358P 2014-10-15 2014-10-15
US201462092041P 2014-12-15 2014-12-15
PCT/US2015/055487 WO2016061195A1 (en) 2014-10-15 2015-10-14 Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists

Publications (1)

Publication Number Publication Date
NZ731060A true NZ731060A (en) 2023-07-28

Family

ID=55747256

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ731060A NZ731060A (en) 2014-10-15 2015-10-14 Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists

Country Status (22)

Country Link
US (5) US10238659B2 (OSRAM)
EP (2) EP4353310A3 (OSRAM)
JP (1) JP6761410B2 (OSRAM)
KR (1) KR102435956B1 (OSRAM)
CN (2) CN111557942B (OSRAM)
AU (1) AU2015333645B2 (OSRAM)
BR (1) BR112017007860B1 (OSRAM)
CA (1) CA2964625C (OSRAM)
DK (1) DK3206692T3 (OSRAM)
ES (1) ES2978871T3 (OSRAM)
FI (1) FI3206692T3 (OSRAM)
IL (1) IL251729B (OSRAM)
MX (1) MX2017004943A (OSRAM)
NZ (1) NZ731060A (OSRAM)
PH (1) PH12017500710B1 (OSRAM)
PL (1) PL3206692T3 (OSRAM)
PT (1) PT3206692T (OSRAM)
RU (1) RU2718921C2 (OSRAM)
SG (1) SG11201703024VA (OSRAM)
UA (1) UA123537C2 (OSRAM)
WO (1) WO2016061195A1 (OSRAM)
ZA (1) ZA201702813B (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3206692T (pt) 2014-10-15 2024-04-30 Corcept Therapeutics Inc Tratamento da doença hepática gordurosa utilizando antagonistas dos recetores de glicocorticoides e mineralocorticoides
JP7196201B2 (ja) * 2018-06-04 2022-12-26 コーセプト セラピューティクス， インコーポレイテッド ピリミジンシクロヘキセニル糖質コルチコイドレセプター調節因子
KR20210153056A (ko) 2019-03-18 2021-12-16 리네트 케이. 니만 인슐린 감수성 개선 방법
AU2021266739B2 (en) * 2020-05-06 2024-11-28 Corcept Therapeutics Incorporated Formulations of pyrimidine cyclohexyl glucocorticoid receptor modulators
CA3182272A1 (en) 2020-05-06 2021-11-11 Corcept Therapeutics Incorporated Polymorphs of pyrimidine cyclohexyl glucocorticoid receptor modulators
KR102481705B1 (ko) * 2020-08-04 2022-12-27 연세대학교 산학협력단 트리아졸 유도체를 유효성분으로 포함하는 간 섬유증의 예방 또는 치료용 조성물
KR20230124020A (ko) 2020-12-21 2023-08-24 코어셉트 쎄라퓨틱스 인코포레이티드 피리미딘 시클로헥실 글루코코르티코이드 수용체 조절제의제조 방법
AU2022271209A1 (en) * 2021-05-05 2023-11-09 Corcept Therapeutics Incorporated Methods for reducing liver fat and for treating fatty liver disorders
WO2025174745A1 (en) * 2024-02-12 2025-08-21 Corcept Therapeutics Incorporated MIRICORILANT TREATMENT FOR FATTY LIVER DISEASES and its EFFECTS on LIVER FAT CONTENT, FATTY ACIDS, ACYLGLYCEROLS, and SECONDARY BILE ACIDS
WO2025255357A1 (en) * 2024-06-06 2025-12-11 Corcept Therapeutics Incorporated Methods for preparing and maintaining livers and portions thereof for liver transplantation

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2153546A (en) 1936-07-29 1939-04-11 Universal Draft Gear Attachmen Hand brake actuating mechanism
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
GB0213745D0 (en) * 2002-06-14 2002-07-24 Univ Edinburgh Enzyme
EP1534273A4 (en) 2002-07-18 2007-08-22 Bristol Myers Squibb Co MODULATORS OF THE GLUCOCORTICOID RECEPTOR AND METHOD
US7745657B2 (en) 2005-05-18 2010-06-29 Merck Sharp & Dohme Corp. D-homoandrosta-17-yl carbamate derivatives as selective glucocorticoid receptor ligands
WO2007022518A2 (en) 2005-08-19 2007-02-22 Amylin Pharmaceuticals, Inc. New uses of glucoregulatory proteins
EP1941040A1 (en) * 2005-09-19 2008-07-09 Johnson & Johnson Pharmaceutical Research & Development L.L.C. Modulation of glucocorticoid receptor expression
GB0601092D0 (en) * 2006-01-19 2006-03-01 Daniolabs Ltd The Prevention Of Systemic Side-Effects Of Glucocorticoids
ES2546181T3 (es) 2006-05-09 2015-09-21 Genzyme Corporation Métodos de tratar la enfermedad del hígado graso mediante inhibición de la síntesis de glucoesfingolípidos
US9623021B2 (en) 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
MX2009011062A (es) 2007-04-13 2009-10-29 Schering Corp Derivados de pirimidindiona y sus metodos de uso.
US8003689B2 (en) 2008-06-20 2011-08-23 Gtx, Inc. Metabolites of selective androgen receptor modulators and methods of use thereof
AU2010232670B2 (en) 2009-04-03 2015-07-09 F. Hoffmann-La Roche Ag Propane- I-sulfonic acid {3- [5- (4 -chloro-phenyl) -1H-pyrrolo [2, 3-b] pyridine-3-carbonyl] -2, 4-difluoro-pheny l } -amide compositions and uses thereof
JP6039587B2 (ja) 2011-03-18 2016-12-07 コーセプト セラピューティクス， インコーポレイテッド ピリミジンシクロヘキシルグルココルチコイドレセプター調節因子
PT3206692T (pt) 2014-10-15 2024-04-30 Corcept Therapeutics Inc Tratamento da doença hepática gordurosa utilizando antagonistas dos recetores de glicocorticoides e mineralocorticoides

Also Published As

Publication number Publication date
UA123537C2 (uk) 2021-04-21
KR102435956B1 (ko) 2022-08-23
EP3206692A1 (en) 2017-08-23
CN107106562B (zh) 2020-08-18
MX2017004943A (es) 2017-07-19
RU2718921C2 (ru) 2020-04-15
DK3206692T3 (da) 2024-04-29
ES2978871T3 (es) 2024-09-23
RU2017114596A3 (OSRAM) 2019-05-08
US20250221995A1 (en) 2025-07-10
CN111557942B (zh) 2023-10-03
US10238659B2 (en) 2019-03-26
JP6761410B2 (ja) 2020-09-23
JP2017531013A (ja) 2017-10-19
ZA201702813B (en) 2019-05-29
AU2015333645A1 (en) 2017-05-04
US10881660B2 (en) 2021-01-05
EP3206692B1 (en) 2024-04-03
EP4353310A3 (en) 2024-06-19
FI3206692T3 (fi) 2024-05-06
BR112017007860B1 (pt) 2023-03-07
IL251729A0 (en) 2017-06-29
US20230218621A1 (en) 2023-07-13
CA2964625C (en) 2023-03-07
US20160106749A1 (en) 2016-04-21
US20190151318A1 (en) 2019-05-23
AU2015333645B2 (en) 2020-01-30
KR20170066646A (ko) 2017-06-14
PH12017500710A1 (en) 2017-10-09
RU2017114596A (ru) 2018-11-15
PL3206692T3 (pl) 2024-07-22
PH12017500710B1 (en) 2024-01-17
PT3206692T (pt) 2024-04-30
CN107106562A (zh) 2017-08-29
SG11201703024VA (en) 2017-05-30
US11590135B2 (en) 2023-02-28
EP3206692A4 (en) 2018-05-30
CA2964625A1 (en) 2016-04-21
CN111557942A (zh) 2020-08-21
US20210085682A1 (en) 2021-03-25
IL251729B (en) 2020-03-31
WO2016061195A1 (en) 2016-04-21
US12226417B2 (en) 2025-02-18
BR112017007860A2 (pt) 2018-01-16
EP4353310A2 (en) 2024-04-17

Similar Documents

Publication Publication Date Title
NZ731060A (en) Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists
MX2020014300A (es) Compuestos heterociclicos utiles en el tratamiento de enfermedades.
PH12016501966A1 (en) Compounds and compositions as toll-like receptor 7 agonists
NZ724878A (en) Compounds and compositions as toll-like receptor 7 agonists
MX381417B (es) Inhibidores de glucosidasa.
CL2016002072A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
EA201692316A1 (ru) Производные холана для применения при лечении и/или профилактике fxr и tgr5/gpbar1-опосредованных заболеваний
NZ737399A (en) Ccr2 modulators
NZ720478A (en) Autotaxin inhibitor compounds
PH12016501791B1 (en) Muscarinic receptor agonists
EA201691845A1 (ru) Фармацевтические композиции терапевтически активных соединений
JO3316B1 (ar) مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل
PH12017500401A1 (en) Therapeutic compounds as inhibitors of the orexin-1 receptor
EA201691844A1 (ru) Фармацевтические композиции терапевтически активных соединений
MX2014004074A (es) Metodo de tratamiento de condiciones del higado utilizando antagonistas de notch2.
WO2018067520A3 (en) Therapeutic agents and methods:
EA201791454A1 (ru) Лекарственные формы для трансдермального введения
MX2016014559A (es) Compuestos para el tratamiento de cancer.
PH12017500451A1 (en) Crystalline forms of 6-((6,7-dimethoxyquinazolin-4-yl) oxy)-n, 2-dimethylbenzofuran -3- carboxamide
MX382175B (es) Composiciones de profármaco de monometilfumarato
GEP20186908B (en) P-substituted asymmetric ureas and medical uses thereof
MX2015012318A (es) Formas de estado solido de un derivado de quinazolina y su uso como un inhibidor de braf.
MX369451B (es) Formas cristalinas de compuestos basados en 1, 8- naftiridin-4(h)-ona particulares y su uso en el tratamiento de ansiedad y condiciones relacionadas.
MX371343B (es) Moduladores del receptor x hepatico (lxr).
MX2016002930A (es) Moduladores del receptor x hepatico (lxr).

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 OCT 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20240829

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 OCT 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20250904